Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: CSL Limited

Capitalization 49.67B 42.65B 38.55B 36.91B 67.42B 4,562B 69.54B 454B 182B 2,187B 186B 182B 7,831B P/E ratio 2026 *
36.9x
P/E ratio 2027 * 15x
Enterprise value 58.57B 50.29B 45.46B 43.53B 79.5B 5,379B 82B 535B 214B 2,579B 220B 215B 9,234B EV / Sales 2026 *
3.71x
EV / Sales 2027 * 3.52x
Free-Float
99.9%
Yield 2026 *
2.79%
Yield 2027 * 3.14%
1 day-1.37%
1 week-0.20%
Current month-2.85%
1 month-12.76%
3 months-20.26%
6 months-30.72%
Current year-17.42%
1 week 140.93
Extreme 140.93
147.9
1 month 140.93
Extreme 140.93
160
Current year 140.93
Extreme 140.93
184.62
1 year 140.93
Extreme 140.93
275.79
3 years 140.93
Extreme 140.93
313.55
5 years 140.93
Extreme 140.93
319.78
10 years 91.62
Extreme 91.62
342.75
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Tech/Sci/R&D Officer 64 01/10/2020
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 14/08/2013
Director/Board Member 68 16/02/2016
Change 5d. change 1-year change 3-years change Capi.($)
-1.37%-0.20%-43.40%-49.66% 49.67B
-1.22%+0.70%+3.65%+3.35% 79.23B
-4.79%-4.45%+48.45%+221.07% 58.37B
+0.82%+59.20%+59.20%+59.20% 50.28B
+0.09%+2.39%+25.01%-26.56% 27.65B
-1.36%+10.34%+52.89%-60.24% 21.71B
-1.11%-2.09%+34.99%+33.34% 19.11B
-1.75%+8.63%+111.81%+115.05% 19.03B
-0.87%+0.16%+37.07%+62.79% 14.69B
+13.22%+15.17%+136.69%+428.59% 14.41B
Average +0.39%+4.40%+46.64%+78.69% 35.41B
Weighted average by Cap. -0.70%+3.26%+31.31%+60.88%

Financials

2026 *2027 *
Net sales 15.77B 13.54B 12.24B 11.72B 21.4B 1,448B 22.08B 144B 57.72B 694B 59.17B 57.92B 2,486B 16.42B 14.1B 12.74B 12.2B 22.29B 1,508B 22.99B 150B 60.1B 723B 61.62B 60.31B 2,589B
Net income 1.4B 1.2B 1.09B 1.04B 1.9B 129B 1.96B 12.8B 5.13B 61.67B 5.26B 5.15B 221B 3.33B 2.86B 2.58B 2.47B 4.51B 305B 4.66B 30.41B 12.18B 146B 12.48B 12.22B 524B
Net Debt 8.9B 7.64B 6.91B 6.61B 12.08B 817B 12.46B 81.35B 32.58B 392B 33.4B 32.69B 1,403B 8.19B 7.03B 6.36B 6.09B 11.11B 752B 11.46B 74.85B 29.97B 361B 30.73B 30.08B 1,291B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Employees
29,904
Date Price Change Volume
11/03/26 142.58 $ -1.37% 1,106,022
10/03/26 144.56 $ +1.65% 1,042,834
09/03/26 142.22 $ -2.77% 1,318,863
06/03/26 146.27 $ -0.15% 956,810
05/03/26 146.49 $ +2.54% 1,393,930
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
103.24USD
Average target price
146.29USD
Spread / Average Target
+41.70%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW